Na Yeon Kim - Jul 26, 2022 Form 4/A - Amendment Insider Report for NeuroBo Pharmaceuticals, Inc. (NRBO)

Role
Director, 10%+ Owner
Signature
/s/ Phillip D. Torrence, by Power of Attorney
Stock symbol
NRBO
Transactions as of
Jul 26, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
7/28/2023, 06:02 AM
Date Of Original Report
Jul 28, 2022
Previous filing
Jun 13, 2022
Next filing
Jul 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRBO Common Stock Other $0 +4.67K $0.00 4.67K Jul 26, 2022 Held by E&Investment Inc. F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to add the acquisition of 4,671 shares by E&Investment Inc., which was inadvertently left off the original Form 4.
F2 E&Investment Inc. received a pro rata distribution from E&Healthcare Investment Fund II, of which the reporting person is a limited partner, for no consideration.
F3 The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.
F4 Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.